Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.
|Articles|October 1, 2000
Four controversies in pediatric asthma care
Asthma management has come a long way in recent years, but many dilemmas remain: When is the right time to make the diagnosis and start anti-inflammatory therapy? What about growth suppression from steroids? Is an inhaler or nebulizer best for acute attacks?
Advertisement
Advertisement
Related to this article
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Menstrual irregularities in adolescents: When to investigate
2
FDA proposes cadmium action levels for baby food under Closer to Zero
3
Family-focused behavioral care tied to better HbA1c in pediatric T1D
4
Managing infection risks in children on biologic therapies
5